IM
Immatics N.V.
IMTX · NASDAQ
$8.79 -0.57% (-$0.05)
1M -8.34%
Market Cap 1.01B €
P/E Ratio -
Div. Yield -
ROE 45.39%
Bulios Fair Price
$7.78
11.5% downside
Current Price
$8.79
Undervalued Fair Value Overvalued
According to Bulios Fair Price, IMTX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
38 /100
Fair P/S 24.14x
P/B 2.53x
P/E N/A
Growth
22 /100
Declining Rev. growth 34.64%
Book val. growth 31.43%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 77.79%
FCF margin 501.62%
Net margin 495.95%
Quality
1 /100
Poor ROIC 52.79%
Asset turnover 0.09x
ROE 45.39%
Debt
69 /100
Low Debt/Equity 0.04x
Int. coverage -242.90x
Current ratio 7.54x
Stability
13 /100
Unstable Beta 1.32x
Profitable years 0
Rev. volatility 148.66%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about IMTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Harpreet Singh
Employees
678
Headquarters
Tübingen
Upcoming events
17 NOV
Earnings
Upcoming earnings report